Rasagiline label report the indication to wait at least 14 days between discontinuation of
rasagiline and initiation of another MAO inhibitor. This results in a major inconvenience for
Parkinsonian patients (PD) due to their clinical worsening. Safinamide is a reversible MAO-B
inhibitor, characterized by a good safety profile. In clinical practice safinamide is often
introduced instead of rasagiline following an overnight switch. The aim of this study is to
explore the safety and tolerability of the immediate switch from rasagiline (irreversible
MAO-B inhibitor) to safinamide, with the expectation that there will be no adverse events or
increased risk of hypertensive crisis for patients with PD or signs of serotonin syndrome